Acupuncture/Moxibustion for Irritable Bowel Syndrome (IBS) (Acu/MoxaIBS)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by New York University.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Information provided by:
New York University
ClinicalTrials.gov Identifier:
NCT00945074
First received: July 21, 2009
Last updated: July 22, 2009
Last verified: July 2009

July 21, 2009
July 22, 2009
July 2009
January 2013   (final data collection date for primary outcome measure)
Patient-rated abdominal pain/discomfort and IBS-Secondary symptom rating: intestinal gas, bloating and stool consistency [ Time Frame: Six months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00945074 on ClinicalTrials.gov Archive Site
  • Global improvement (CGIS) [ Time Frame: Six months ] [ Designated as safety issue: No ]
  • Quality of life (IBS-QOL & SF-36) [ Time Frame: Six months ] [ Designated as safety issue: No ]
  • Psychological distress (SCL-90) [ Time Frame: Six months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Acupuncture/Moxibustion for Irritable Bowel Syndrome (IBS)
Protocol- vs. Patient-Oriented TCM Practices: A RCT for IBS Symptom Management

The objective of this study is to test the efficacy of a symptom management treatment strategy, namely, Acupuncture/Moxibustion (Acu/Moxa) to improve the symptoms associated with Irritable Bowel Syndrome (IBS) in persons between the ages of 18 to 70 years.

IBS has been defined as abdominal pain or discomfort in the mid or lower gastrointestinal (GI) tract, associated with defecation or a change in bowel patterns and with features of disordered defecation. Current therapies include dietary modification, psychotherapy and pharmacological therapies. Traditional eastern approaches offer a therapeutic approach to symptom management that is subtle, holistic and holds promise as an intervention for IBS.

This study will enroll 171 men and women experiencing IBS with diarrhea (IBS-D) defined by the ROME III criteria. Subjects will be randomized (by chance) to one of three experimental intervention conditions: Condition 1,subjects receive Standard Acu/Moxa; Condition 2, subjects receive Individualized Acu/Moxa and Condition 3, subjects receive Sham Acupuncture/Placebo Moxibustion(control group).

Subjects will attend a screening/intake session followed by two treatment sessions per week for 4 weeks, one treatment session per week for 4 weeks, and 2 non-treatment follow-up sessions at weeks 12 and 24. All subjects will be assessed by a diagnostic acupuncturist (blinded to treatment assignments), receive interventions appropriate to their condition assignment by treating acupuncturists, be administered the same instruments, and submit their symptom diaries for data entry and analysis. All subjects will complete a prospective symptom diary for the duration of the study.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Irritable Bowel Syndrome
  • Other: Standard Acupuncture/Moxibustion (fixed protocol)
    Acupuncture/Moxibustion
  • Other: Individualized Acupuncture/Moxibustion
    Individualized Tailored Acupuncture/Moxibustion Protocol based on TCM Diagnosis
  • Other: Sham/Placebo Acupuncture/Moxibustion
    Sham/Placebo Acupuncture/Moxibustion Protocol: Not-Active
  • Experimental: Condition 1

    Condition 1:

    Subjects receive Standard Acu/Moxa (fixed protocol)

    Intervention: Other: Standard Acupuncture/Moxibustion (fixed protocol)
  • Experimental: Condition 2: Individualized Acupuncture/Moxibustion

    Condition 2:

    Subjects receive Individualized Acupuncture/Moxibustion (patient-oriented, based on traditional Chinese medicine diagnosis).

    Intervention: Other: Individualized Acupuncture/Moxibustion
  • Sham Comparator: Condition 3: Control

    Condition 3:

    Subjects receive Sham Acupuncture/Placebo Moxibustion (control group)

    Intervention: Other: Sham/Placebo Acupuncture/Moxibustion
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
171
March 2013
January 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Men and women 18 to 70 years of age who have a prior diagnosis of IBS (6 months or greater)
  • Verification/documentation of subject's diagnosis of IBS (ROME III criteria).
  • Subjects must be experiencing recurrent abdominal pain/discomfort with two or more of the following, as described in the Rome III criteria: (1) Improvement with defecation; and/or (2) Onset associated with a change in frequency of stool; and/or (3) Onset associated with a change in form (appearance) of stool.
  • Four-week prospective daily symptom diary must show: IBS with diarrhea IBS-D), defined by ROME III
  • Subjects agree to complete symptom diaries and return completed diaries at all sessions.
  • Women of childbearing age must agree to use an acceptable method of contraception.
  • Subjects may be on antidepressants(on stable regimen for at least 6 months)

Exclusion Criteria:

  • Individuals who have IBS-Mixed, IBS-Unspecified or IBS-Constipation
  • Individuals who have a history of co-existing gastrointestinal, and/or gynecological, and/or urologic pathology (eg., colon cancer, colitis, Crohn's, celiac, endometriosis, prostate cancer) or lactose intolerance
  • Individuals experiencing alarm symptoms according to Rome III
  • Abdominal surgery, with the exception of uncomplicated removal of the appendix, uterus, or gallbladder more than 6 months prior to study entry.
  • Individuals who are currently taking the following medications more than 3 days a week: antibiotics, narcotics, cholestyramine, colchicine, iron supplements, antispasmotics, benzodiazepines
  • Individuals currently receiving other types of complementary therapies such as herbs, massage, reiki etc.;Individuals receiving behavioral therapies for IBS; Individuals receiving physical therapy for pelvic pain
  • Pregnant women.
  • Individuals with an acute medical condition, i.e., pneumonia and/or conditions that requiring acute medical attention.
  • Individuals with asthma or smoke allergy
  • Individuals receiving acupuncture currently and less than 6 months prior to enrollment and/or history of receiving moxibustion
  • Individuals with plans for travel, lifestyle change, or other activity that would preclude attending the planned study sessions or recording daily dietary information.
Both
18 Years to 70 Years
No
Contact: Ann M Chung 212-922-7038 amc20@nyu.edu
Contact: Colin Scully 212-922-7051 csg6@nyu.edu
United States
 
NCT00945074
7833948, R01NR010730
No
Dr. Joyce K. Anastasi, Principal Investigator, New York University
New York University
National Institutes of Health (NIH)
Principal Investigator: Joyce K Anastasi, PhD, DrNP, FAAN, LAc New York University
New York University
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP